Persson B, Andersson O K, Wysocki M, Hedner T, Karlberg B
Department of Medicine, Sahlgren's Hospital, University of Gothenburg, Sweden.
J Intern Med. 1992 Mar;231(3):247-52. doi: 10.1111/j.1365-2796.1992.tb00531.x.
Sixteen middle-aged men with primary hypertension were treated with the calcium antagonist isradipine over a 9-week period in a randomized, placebo-controlled, double-blind cross-over manner. At the end of the intervention period the urinary albumin excretion rate, systemic and renal haemodynamics, haemorheological properties of blood and plasma concentrations of atrial natriuretic peptide, noradrenaline and peripheral renin activity were determined. Treatment with isradipine resulted in a substantial reduction in blood pressure due to a reduction in peripheral resistance. The mean albumin excretion rate was not influenced by the isradipine treatment. In a multivariate analysis, changes in the urinary albumin excretion rate were only related to changes in blood pressure.
16名原发性高血压中年男性患者，采用随机、安慰剂对照、双盲交叉方式，接受钙拮抗剂伊拉地平治疗9周。在干预期结束时，测定尿白蛋白排泄率、全身和肾脏血流动力学、血液流变学特性以及心房利钠肽、去甲肾上腺素的血浆浓度和外周肾素活性。伊拉地平治疗通过降低外周阻力使血压大幅下降。伊拉地平治疗对平均白蛋白排泄率无影响。在多变量分析中，尿白蛋白排泄率的变化仅与血压变化有关。
